Quintana-Villamandos Begoña, Pazó-Sayós Laia, González Del Pozo Irene, Rodríguez-Rodríguez Pilar, Bellón Jose María, Pedraz-Prieto Álvaro, Pinto Ángel G, González Maria Carmen
Department of Anesthesiology Hospital Gregorio Marañón. C/, Doctor Esquerdo Nº 46, Madrid, 28007, Spain Department of Pharmacology and Toxicology, Faculty of Medicine, Universidad Complutense, Madrid, Spain.
Department of Anesthesiology and Intensive Care, Gregorio Marañón Hospital, Madrid, Spain.
Ther Adv Chronic Dis. 2020 Jun 27;11:2040622320936417. doi: 10.1177/2040622320936417. eCollection 2020.
A recently developed global indicator of oxidative stress (OXY-SCORE), by combining individual plasma biomarkers of oxidative damage and antioxidant capacity, has been validated in several pathologies, but not in left ventricular hypertrophy (LVH). The aim of this study was to design and calculate a plasma oxidative stress global index for patients with LVH.
A total of 70 consecutive adult patients were recruited in our institution and assigned to one of the two study groups (control group/LVH group) by an echocardiography study. We evaluated plasmatic biomarkers of oxidative damage (malondialdehyde and thiolated proteins) and antioxidant defense (total thiols, reduced glutathione, total antioxidant capacity, catalase, and superoxide dismutase activities) by spectrophotometry/fluorimetry in order to calculate a plasma oxidative stress global index (OXY-SCORE) in relation to LVH.
The OXY-SCORE exhibited a highly significant difference between the groups ( < 0.001). The area under the receiver operating characteristic curve was 0.74 (95% confidence interval (CI), 0.62-0.85; < 0.001). At a cut-off value of -1, the 68.6% sensitivity and 68.6% specificity values suggest that OXY-SCORE could be used to screen for LVH. A multivariable logistic regression model showed a positive association ( = 0.001) between OXY-SCORE and LVH [odds ratio = 0.55 (95% CI, 0.39-0.79)], independent of gender, age, smoking, glucose, systolic and diastolic arterial pressure, dyslipidemia, estimated glomerular filtration rate, body mass index, and valvular/coronary disease.
OXY-SCORE could help in the diagnosis of LVH and could be used to monitor treatment response.
最近开发的一种通过结合个体血浆氧化损伤生物标志物和抗氧化能力的氧化应激全球指标（OXY-SCORE）已在多种疾病中得到验证，但尚未在左心室肥厚（LVH）中得到验证。本研究的目的是为LVH患者设计并计算血浆氧化应激全球指数。
在我们机构共招募了70名连续的成年患者，并通过超声心动图研究将其分配到两个研究组之一（对照组/LVH组）。我们通过分光光度法/荧光法评估氧化损伤（丙二醛和硫醇化蛋白）和抗氧化防御（总硫醇、还原型谷胱甘肽、总抗氧化能力、过氧化氢酶和超氧化物歧化酶活性）的血浆生物标志物，以计算与LVH相关的血浆氧化应激全球指数（OXY-SCORE）。
两组之间OXY-SCORE存在高度显著差异（<0.001）。受试者工作特征曲线下面积为0.74（95%置信区间（CI），0.62 - 0.85；<0.001）。在临界值为 -1时，68.6%的敏感性和68.6%的特异性值表明OXY-SCORE可用于筛查LVH。多变量逻辑回归模型显示OXY-SCORE与LVH之间存在正相关（=0.001）[比值比 = 0.55（95%CI，0.39 - 0.79）]，独立于性别、年龄、吸烟、血糖、收缩压和舒张压、血脂异常、估计肾小球滤过率、体重指数以及瓣膜/冠状动脉疾病。
OXY-SCORE有助于LVH的诊断，并可用于监测治疗反应。
